Daewoong Pharmaceutical’s Nabota Acquires Marketing Authorization in the UAE and Indonesia… Advancing into the Halal Market

Daewoong Pharmaceutical’s Nabota Acquires Marketing Authorization in the UAE and Indonesia… Advancing into the Halal Market - Gathering momentum as the first in Korea for global expansion with its botulinum toxin product entering the UAE and Indonesia - Acquired marketing authorization from 50 countries worldwide as well as sales agreements signed with 80 countries Nabota, a botulinum toxin product developed by Daewoong Pharmaceutical (Daewoong), advances into the halal market and gains momentum as a global brand. Daewoong (CEO Sengho Jeon) announced on March 19 that the company has obtained marketing authorization for Nabota in the UAE and Indonesia, two halal countries. The UAE Ministry of Health and the Indonesian National Agency of Drug and Food Control approved Nabota for an indication of glabellar wrinkles. As Nabota obtained marketing authorization in the UAE and Indonesia, being the first in Korea, as a botulinum toxin product, it further solidifies its position in not just the US, Europe and Canada, but also the Middle East and Asia. In particular, the UAE is the first country in the Middle East which Nabota is entering, and Daewoong is planning to use this as a bridge to accelerate the product’s marketing authorization in other countries across the Middle East. Daewoong will release Nabota in the UAE and Indonesia in the first half of 2020. The local partner Dansys will be the one which sells Nabota in the UAE. Dansys is a company which specializes in aesthetics with a strong sales network in the Middle East and experience spanning for more than a decade in the skin and beauty business. Daewoong has signed an exclusive supplier deal with Dansys in March 2017 for eight Middle Eastern countries, including the UAE and Kuwait. Seongsoo Park, head of Daewoong’s Neurotoxin Business Division, said, “Not only does the pharmaceutical market continues to grow in both countries, but the UAE also can serve as a bridge for us to advance into other regions in the Middle East, and Indonesia has the fourth largest population in the world with great growth potential. In 2020, we will further expand the influence of Nabota in the global market by obtaining new marketing authorization in other pharmerging markets while enhancing our position in advanced countries.” Meanwhile, Daewoong’s botulinum toxin product has obtained marketing authorization from 50 countries worldwide including the US, Canada and Europe, and signed sales agreements with 80 countries. #   #   # [Photograph courtesy of Daewoong Pharmaceutical] Nabota, a botulinum toxin product developed by Daewoong Pharmaceutical, obtained marketing authorization in the UAE and Indonesia.

The release as fetched from its publisher. daewoong.co.kr ↗